Consequently, POC as well as molecular diagnostic tests are available and are under development for cardiology monitoring, oncology testing, and hematology testing. Ongoing research and development are continually supported as well as funded by several international entities by the governments of developed countries.įurthermore, a growing portfolio of point-of-care testing capabilities that are focused on screening, testing, and diagnosis of infectious diseases in low-income developing countries, has been developing at a rapid pace over the past decade to expand its potential market to a broader range of medical faculties.
#Poc molecular diagnostics portable#
The increasing demand for CLIA tests that are portable as well as safe enough to be used in non-laboratory settings such as pharmacy clinics, physician offices, and home-care settings will drive demand in the market over the forecast period. > Ask For Discount – Global Point-Of-Care Molecular Diagnostics Market Overview All three steps can be performed together or separately according to the convenience of the doctors and physicians. Three basic steps are required for each molecular analysis, The first step is extraction and purification of nucleic acid, followed by the second step which is amplification or making copies of the nucleic acid of interest (target) or attaching multiple copies of a dye to a single target copy, and third and the last step is the detection of the amplified target using real-time polymerase chain reaction (PCR) or end product detection including microarrays, Luminex i.e. The clinical applications of molecular diagnostics can be found in at least six wide-ranging areas which are oncology, pharmacogenomics, human leukocyte antigen typing, infectious diseases, genetic disease screening, and coagulation. These tests are used to detect specific sequences in DNA or RNA that are associated with diseases such as single nucleotide polymorphism (SNP), insertions, rearrangements, deletions, and others. Molecular technologies are employed that tests the nucleic acid as well as the DNA of the patient for the detection of any pathogens, infections, tumors, or abnormalities. It also eliminates the follow-up visits of the patient.
The test results are fast and thus ensure that timely treatment is offered to the patients. POC molecular diagnostics is fast as well as efficient and therefore reaches more patients. It can be done in a hospital, clinic, ambulance, field, or physician’s office. Point-Of-Care (POC) molecular diagnostics are the tests that are performed at a site near the patient.
#Poc molecular diagnostics pdf#
Based on the self-developed isothermal molecular detection technology, Pluslife's Molecular POCT detection system can be used in comprehensive application scenarios such as human respiratory infections, STD infections, and animal diseases.To Get Detailed Analysis: Download Report PDF Global Point-Of-Care Molecular Diagnostics Market Definition Pluslife holds patents for technologies in multiple fields. With the R&D team that combines experienced and talented researching and developing personnel that more than 60% of them are certificated Ph.Ds or Masters, our team satisfies the need of applying cutting-edge genetic technologies to develop an independent and innovative molecular POCT diagnostic system that provides complete and economic solutions to IVD users.
Pluslife Biotech was established in 2017. For more information, please visit: About Pluslife Biotech FIND is a co-convener of the Access to COVID-19 Tools (ACT) Accelerator diagnostics pillar and a WHO Collaborating Centre for Laboratory Strengthening and Diagnostic Technology Evaluation. FIND is working to save 1 million lives through accessible, quality diagnosis, and save US$1 billion in healthcare costs to patients and health systems. FIND connects countries and communities, funders, decision-makers, healthcare providers, and developers to spur diagnostic innovation and make testing an integral part of sustainable, resilient health systems. “FIND and Pluslife shared the same goal to spur diagnostic innovation and make diagnostic more accessible to the public, it is truly a significant social responsibility for Pluslife to honor,” commented Pluslife CEO Noah Chen, “Pluslife Next-Generation POC molecular system will be launched as a reformed method to improve the resilience of the different health channels, and finally achieves more accessible and affordable test for all.”įIND, the global alliance for diagnostics seeks to ensure equitable access to reliable diagnoses around the world.
0 kommentar(er)
